Maxalt for Adolescent Migraines
Yes, Maxalt (rizatriptan) can be used for a 12-year-old adolescent with migraines and is specifically recommended by the 2020 AAN/American Headache Society guidelines as a Level B treatment option for adolescents. 1
Recommended Dosing
Use weight-based dosing:
- 5 mg (orally disintegrating tablet) for patients weighing <40 kg
- 10 mg (orally disintegrating tablet) for patients weighing ≥40 kg 1, 2
The orally disintegrating tablet (ODT) formulation is preferred as it was the formulation studied in pediatric trials and doesn't require water, which is practical for adolescents 1.
Key Treatment Principles
Counsel the patient to treat early in the attack rather than waiting for pain to become severe 1. This is critical for triptan efficacy.
Allow only one dose per 24-hour period 3. Do not permit redosing within the same day, as this increases risk of medication overuse headache and adverse events.
Efficacy Evidence
The evidence for rizatriptan in adolescents shows:
- Pain freedom at 2 hours: 30.6% with rizatriptan vs 22% with placebo (statistically significant, p=0.025) 2
- Pain relief at 2 hours: 77% in long-term studies 4
- Consistent treatment effect maintained over 12 months of use 3
Important caveat: The FDA label states "safety and effectiveness in pediatric patients have not been established" and notes that a randomized controlled trial in 291 adolescents failed to establish efficacy 5. However, rizatriptan is FDA-approved for ages 6-17 years based on other trial data, and the 2020 AAN guidelines specifically recommend it despite acknowledging the mixed trial results 1. The guideline authors note that rizatriptan received "lukewarm recommendations" due to high placebo response rates in parallel-design trials, even though it met FDA approval standards 1.
Contraindications
Absolute contraindications:
- Ischemic heart disease or coronary artery vasospasm
- Cerebrovascular disease (stroke/TIA)
- Peripheral vascular disease
- Uncontrolled hypertension
- Hemiplegic or basilar migraine
- Use of MAO inhibitors within 2 weeks
- Use of ergotamine-containing medications within 24 hours
- Use of another triptan within 24 hours
Screen for cardiovascular risk factors before prescribing, though these are rare in 12-year-olds.
Safety Profile
Rizatriptan was generally well tolerated in long-term pediatric studies (up to 12 months) 3:
- Most common adverse events: dry mouth, dizziness, asthenia/fatigue, nausea, somnolence (all ≤5% incidence) 6
- Only 2.3% discontinued due to adverse events in long-term study 3
- No serious drug-related adverse events except those associated with overdosing (>1 dose/24 hours) 3
Treatment Algorithm
First-line approach: Start with ibuprofen (400-600 mg) for mild-to-moderate attacks 1
Second-line approach: Use rizatriptan ODT (weight-based dosing) for:
- Severe attacks
- Moderate attacks that don't respond to NSAIDs
- Attacks with rapid pain escalation 1
If rizatriptan fails: Try a different triptan (sumatriptan nasal, zolmitriptan nasal, or almotriptan oral) or combine an NSAID with a triptan 1
Critical Pitfalls to Avoid
Medication overuse headache: Counsel strongly about limiting acute medication use to <10 days per month for triptans and avoiding daily or near-daily use 1. This is the most common pitfall in adolescent migraine management.
Weekend vs. weekday treatment: Post-hoc analyses suggest rizatriptan may be more effective when used on weekends vs. school days (possibly due to stress/timing factors), though this shouldn't limit prescribing 4, 6.
Pregnancy considerations: While unlikely relevant for a 12-year-old, for older adolescent females, rizatriptan is Pregnancy Category C. Discuss contraception if relevant 5.